Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study.
about
Pazopanib in the management of advanced soft tissue sarcomasThe clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and EribulinTreatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
P2860
Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Differences in the responses t ...... ibility for the PALETTE study.
@en
type
label
Differences in the responses t ...... ibility for the PALETTE study.
@en
prefLabel
Differences in the responses t ...... ibility for the PALETTE study.
@en
P2093
P2860
P356
P1476
Differences in the responses t ...... gibility for the PALETTE study
@en
P2093
Junichi Tomomatsu
Keisuke Ae
Kenji Nakano
Lina Inagaki
Seiichi Matsumoto
Shunji Takahashi
Tabu Gokita
Taisuke Tanizawa
Takashi Shimoji
P2860
P304
P356
10.1093/JJCO/HYV022
P50
P577
2015-02-26T00:00:00Z